Literature DB >> 15975938

Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse.

Yingli Wang1, Ran Xiao, Fan Yang, Baktiar O Karim, Anthony J Iacovelli, Juanliang Cai, Charles P Lerner, Joan T Richtsmeier, Jen M Leszl, Cheryl A Hill, Kai Yu, David M Ornitz, Jennifer Elisseeff, David L Huso, Ethylin Wang Jabs.   

Abstract

Apert syndrome is an autosomal dominant disorder characterized by malformations of the skull, limbs and viscera. Two-thirds of affected individuals have a S252W mutation in fibroblast growth factor receptor 2 (FGFR2). To study the pathogenesis of this condition, we generated a knock-in mouse model with this mutation. The Fgfr2(+/S252W) mutant mice have abnormalities of the skeleton, as well as of other organs including the brain, thymus, lungs, heart and intestines. In the mutant neurocranium, we found a midline sutural defect and craniosynostosis with abnormal osteoblastic proliferation and differentiation. We noted ectopic cartilage at the midline sagittal suture, and cartilage abnormalities in the basicranium, nasal turbinates and trachea. In addition, from the mutant long bones, in vitro cell cultures grown in osteogenic medium revealed chondrocytes, which were absent in the controls. Our results suggest that altered cartilage and bone development play a significant role in the pathogenesis of the Apert syndrome phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975938     DOI: 10.1242/dev.01914

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  86 in total

1.  Mesodermal expression of Fgfr2S252W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome.

Authors:  Greg Holmes; Claudio Basilico
Journal:  Dev Biol       Date:  2012-06-01       Impact factor: 3.582

2.  The balance of WNT and FGF signaling influences mesenchymal stem cell fate during skeletal development.

Authors:  Takamitsu Maruyama; Anthony J Mirando; Chu-Xia Deng; Wei Hsu
Journal:  Sci Signal       Date:  2010-05-25       Impact factor: 8.192

Review 3.  The role of vertebrate models in understanding craniosynostosis.

Authors:  Greg Holmes
Journal:  Childs Nerv Syst       Date:  2012-08-08       Impact factor: 1.475

Review 4.  The molecular and cellular basis of Apert syndrome.

Authors:  Chao Liu; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-11

5.  Mouse models of Apert syndrome.

Authors:  Greg Holmes
Journal:  Childs Nerv Syst       Date:  2012-08-08       Impact factor: 1.475

6.  Morphological comparison of the craniofacial phenotypes of mouse models expressing the Apert FGFR2 S252W mutation in neural crest- or mesoderm-derived tissues.

Authors:  Yann Heuzé; Nandini Singh; Claudio Basilico; Ethylin Wang Jabs; Greg Holmes; Joan T Richtsmeier
Journal:  Bone       Date:  2014-03-13       Impact factor: 4.398

7.  Postnatal brain and skull growth in an Apert syndrome mouse model.

Authors:  Cheryl A Hill; Neus Martínez-Abadías; Susan M Motch; Jordan R Austin; Yingli Wang; Ethylin Wang Jabs; Joan T Richtsmeier; Kristina Aldridge
Journal:  Am J Med Genet A       Date:  2013-03-12       Impact factor: 2.802

Review 8.  Hand in glove: brain and skull in development and dysmorphogenesis.

Authors:  Joan T Richtsmeier; Kevin Flaherty
Journal:  Acta Neuropathol       Date:  2013-03-23       Impact factor: 17.088

9.  Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.

Authors:  Yingli Wang; Miao Sun; Victoria L Uhlhorn; Xueyan Zhou; Inga Peter; Neus Martinez-Abadias; Cheryl A Hill; Christopher J Percival; Joan T Richtsmeier; David L Huso; Ethylin Wang Jabs
Journal:  BMC Dev Biol       Date:  2010-02-22       Impact factor: 1.978

10.  Mesenchymal fibroblast growth factor receptor signaling regulates palatal shelf elevation during secondary palate formation.

Authors:  Kai Yu; Kannan Karuppaiah; David M Ornitz
Journal:  Dev Dyn       Date:  2015-08-24       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.